We investigated if deguelin, a naturally occurring rotenoid, was able to inhibit nuclear factor kappa B (NF-jB)-binding protein (IjBa) expression and to induce apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells in vitro. Deguelin-induced cell death in the majority of B-CLL cells and was found to be more toxic toward B-CLL cells than to the normal mononuclear or B-cells, suggesting selectivity towards the malignant cells. Deguelin was found to reduce IjBa protein expression, and thus interacts with the NFjB pathway. The induced apoptosis was characterized by processing of caspase-9 and -3 and poly-(ADP)-ribose-polymerase cleavage. Exposure of B-CLL cells to deguelin resulted in Bcl2-associated protein (Bax) conformational changes and downregulation of the key survival protein myeloid cell leukemia sequence 1 (Mcl-1), which is associated with response to treatment in B-CLL patients. Deguelin retained its ability to induce apoptosis in B-CLL cells in the presence of interleukin-4, a pro-survival cytokine in B-CLL, and when cultured with 50% human serum. These data indicate that deguelin is able to induce apoptosis in B-CLL cells in the presence of pro-survival signals and thus merits further investigation for clinical application either as a single agent or in combination with other anticancer agents.
Introduction
Plant medicines and medicines derived from plants have been used worldwide for thousands of years. 1 There is resurging interest in the possible use of natural products for treatment of malignant disease 2 and their potential for further chemical modification.
Deguelin is an example of a natural compound recently described to have potential as a cancer chemopreventive or inhibitor of carcinogenesis. 3, 4 The plant derived rotenoid deguelin, most commonly used as an insecticide in Africa and South America, has been isolated from several plant species, including Mundulae sericea (Leguminosae). 5 So far, the potential of deguelin as a cancer chemotherapeutic agent was suggested in several cancers, including colon cancer 6 and skin or mammary tumorigenesis models. 7 In addition, deguelin was suggested to be useful for chemoprevention and the induction of apoptosis in lung carcinogenesis and for therapy in confirmed lung cancer. [8] [9] [10] [11] [12] It was shown that the pro-apoptotic activity of deguelin in premalignant and malignant bronchial epithelial cells was caused by the inhibition of phosphoinositide-3 kinase (PI3K) activity and the reduction of Akt phosphorylation. 12 Furthermore, Bortul et al. 13 described that deguelin might be used in the future for increasing sensitivity to therapeutic treatments of leukemic cells with an active PI3K/Akt signaling network. Because activated Akt can affect numerous cellular functions via intermediary molecules, including mTOR, NF-kB and p53, which control cell survival, growth and proliferation, effective inhibition of PI3K/Akt by deguelin means it can affect the activation of NF-kB. 14 Recently, Chen et al. 14 described that deguelin interacts with the NF-kB pathway and inhibits the expression of IkBa protein in Raji and U937 cells combined with the induction of apoptosis in U937 cells.
B-cell chronic lymphocytic leukemia (B-CLL) is a clinically heterogeneous disease characterized by the accumulation of malignant CD5
þ B lymphocytes. [15] [16] [17] Most circulating cells appear to be nondividing and the clonal excess of B cells results from decreased apoptosis rather then increased proliferation. 18 However, the molecular mechanism controlling apoptosis in B-CLL is complex and is influenced by many factors. 19 During the past decade, major advances in the therapy of B-CLL have been made, including the emergence of promising first-line agents, such as the nucleoside analog fludarabine and the monoclonal antibodies Campath-H1 (anti-CD52) and rituximab (anti-CD20). 20 However, despite these and other therapeutic options, eventual lethal progression is common, particularly in patients with leukemia cells with unmutated IgV H genes (UM-CLL). 21 Thus, continued preclinical studies on innovative therapeutic strategies are warranted. The identification of new agents that interfere with the survival of B-CLL cells by promoting their apoptosis is one approach to improve therapeutic outcome. 22 Several studies suggest that CLL may have constitutive activation of NF-kB, which appears to enhance leukemia-cell survival. 23, 24 In addition, Inhibitors of the canonical NF-kB pathway are suggested to have therapeutic activity in this disease. 25 We investigated if deguelin was able to reduce the expression of the IkBa protein and to induce apoptosis in B-CLL cells in vitro. Therefore, we evaluated the processing of caspases, expression or conformational changes of pro-and anti-apoptotic proteins and the cleavage of poly-(ADP)-ribose-polymerase (PARP). Furthermore, we examined the potential of deguelin to induce apoptosis in B-CLL cells in the presence of 50% human serum, as it is known that a compound can be associated with human serum albumin even in the absence of binding to fetal bovine serum (FBS). In addition, we investigated if prosurvival signals such as interleukin 4 (IL-4) could interfere with the pro-apoptotic effect of deguelin on B-CLL cells.
Materials and methods

Cell isolation, culture and reagents
Blood samples were obtained from patients fulfilling diagnostic and immunophenotypic criteria for common B-CLL 26 after giving informed consent according to institutional guidelines. Blood mononuclear cells were isolated by density-gradient centrifugation over Ficoll-Hypaque (Pharmacia, Uppsala, Sweden). The mutational and ZAP-70 status was determined as described previously 27 (Table 1) . Sequences with less than 98% homology to the corresponding germ-line IgV H sequence were considered to be mutated. 27 ZAP-70 levels above 20% were considered as positive. 27 Normal peripheral blood mononuclear cells (PBMCs) were obtained from healthy volunteers following informed consent and isolated in the same manner. Freshly isolated B-CLL cells and normal PBMCs were used. The viability was determined by trypan blue counting and was 98 to 99% for all samples at the start of each experiment. During the experiments, B-CLL cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Gibco, Invitrogen Inc., Grand Island, NY, USA), containing 10% FBS (or AIM-V s serum-free medium (Gibco, Invitrogen Inc.) when indicated). Deguelin was obtained from Sigma (Steinheim, Germany), and its purity was 499% (by high-performance liquid chromatography). Deguelin was dissolved in dimethyl sulfoxide (DMSO) (Sigma) to obtain a stock solution of 10 À3 M. The final concentration of DMSO in each sample was 0.1%.
Apoptosis assays
For flow cytometric analysis of apoptosis, B-CLL cells were treated with deguelin for 24 to 48 h, 3 Â 10 5 cells were removed from the culture, washed twice with cold phosphate-buffered saline (PBS), and double stained with Annexin V-fluorescein isothiocyanate (FITC) and propidium iodide (PI) (BD Biosciences, San Jose, CA, USA) in Annexin-binding buffer, followed by analysis on a FC500P TM (Beckman Coulter, Nyon, Switzerland) flow cytometer. Flow cytometric data were analyzed using Cytomixs RXP software (Beckman Coulter, Nyon, Switzerland). To avoid nonspecific fluorescence from dead cells, live cells were gated using forward and side scatter. Samples obtained from the same patient, but taken at different timepoints, and added to the analysis to perform the Western blot analysis.
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Evaluation of Apoptosis in CD19-positive cells using serum-free AIMV medium
For flow cytometric analysis of apoptosis in CD19-positive cells, three B-CLL cell samples (two from cryo-storage) and three mononuclear cell samples from healthy volunteers were cultured in serum-free AIM-V medium (Gibco, Invitrogen Inc.). Cells were treated with deguelin for 48 h. A portion of cells (3 Â 10 5 ) was removed from the culture, washed twice with cold PBS with 1% BSA, and double stained with CD19-PECy7 (BD biosciences) and Annexin VFITC (BD biosciences). Flow cytometric analysis was performed as described above.
Western blot analysis
Cells were washed three times with ice-cold PBS before lyses. Cells were lysed with lysis buffer containing 1% Triton X-100, 1% Nonidet P-40, and the following protease and phosphatase inhibitors: aprotinin (10 mg/ml), leupeptin (10 mg/ml) (ICN Biomedicals, Asse-Relegem, Belgium), phenylmethylsulfonyl fluoride (1.72 mM), NaF (100 mM), NaVO 3 (500 mM) and Na 4 P 2 O 7 (500 mg/ml) (Sigma). Equal amounts of proteins were separated on a 10% SDS-polyacrylamide gel, transferred onto nitrocellulose membranes and the protein transfer was checked by Ponceau S solution staining (Sigma). Immunostaining of the blots was performed using the primary antibodies, followed by the secondary antibody conjugated to horseradish peroxidase and detection by enhanced chemiluminescence ( 
Flow cytometric detection of intracellular proteins
B-CLL cell samples were cultured in serum-free AIM-V medium (Gibco, Invitrogen Inc.). Cells were treated with 10 À5 M deguelin for 24 h. Cells were removed from the culture, fixed with 3% formaldehyde and permeabilized with 100% cold methanol. Immunostaining was performed using a primary antibody (1 mg/ 10 6 cells) followed by the secondary goat anti-mouse antibody conjugated to Alexa fluor 488 (Invitrogen) (1/1000). Primary antibodies were either mouse mAb for Bax (YTH-6A7) IgG 1 (Trevigen Inc., Gaithersburg, MD, USA), Caspase-8 (1C12) mouse mAb or mouse isotype control IgG 1 (Caltag Invitrogen Inc., Burlingame, CA, USA).
IL-4 studies
B-CLL cells were cultured at a density of 1 Â 10 6 /ml in DMEM, containing 10% FBS supplemented with 25 ng/ml recombinant human IL-4 (Peprotech EC, London, UK). After 30 min, 10 mM deguelin was added to cultures. At 24 or 48 h later, apoptosis was analyzed using the Annexin V-FITC/PI staining method described above.
Statistical analysis
The Student's t-test was used for testing statistical significance between the two groups. The P-value was considered significant when it was less than 0.05.
Results
Deguelin induces apoptotic cell death in B-CLL cells in vitro
To determine if deguelin is able to induce apoptosis in B-CLL cells in vitro, B-CLL cells from 18 patients with B-CLL were incubated in the absence or presence of deguelin and the percentage of early-apoptotic and viable cells was evaluated by Annexin V/PI flow cytometry after 24 and 48 h. The majority of the B-CLL samples tested (n ¼ 22, four duplicates) showed an apoptotic response to deguelin. Results of deguelin treatment in all samples are shown in Table 1 , including the increase of the percentage early-apoptotic cells (increase over the spontaneous apoptosis in mock-treated control samples) and the reduced viability (viability in the mock-treated control samples was set at 100% as reference) after 24 and 48 h, respectively.
B-CLL cells were incubated with various concentrations of deguelin (from 10 À9 to 10 À5 M) for either 24 or 48 h to evaluate the dose dependency of the pro-apoptotic effect of deguelin ( Figure 1 ). Induction of apoptosis was observed starting at (Figure 1a) . We can conclude that the effect of deguelin on the viability of B-CLL cells is mainly due to increased apoptosis and not to necrosis as evidenced by the increased population of early-apoptotic cells. Additional evidence for an increase in apoptosis is the increase in total percentage of Annexin V-positive cells, a measurement that includes secondary apoptotic cells (Figure 1c) .
The percentage of non-apoptotic, viable cells was evaluated after 48 h incubation of B-CLL cells with various concentrations of deguelin (from 10 À9 to 10 À5 M) by measuring the total percentage of Annexin V-negative/PI-negative cells (Figure 1b 
À6 M deguelin; the results are shown in Table 1 
À6 M deguelin resulted in a small decrease of the average % viable (Annexin V-negative/PI-negative) cells in the PBMC cultures (Figure 2b ). Viable cells in these cultures accounted for 90.9% (average value, n ¼ 6, s.d. 3.14), relative to the medium control (0.1% DMSO), compared to only 52.7% (average value, n ¼ 16, s.d. 17.0) in deguelin-treated B-CLL cells. We can conclude that the sensitivity of normal PBMCs to deguelin is significantly lower than that of B-CLL cells. These data support the conclusion that B-CLL cells are significantly more susceptible to deguelin-induced apoptosis in comparison with normal PBMCs.
We further examined if CLL samples with different mutational status or ZAP-70 expression levels showed different responses to deguelin treatment in vitro (Figures 2c and d) . In general, the expression of ZAP-70 (ZAP þ ) and the absence of somatic mutations in the immunoglobulin genes IgV H (UM-CLL) are predictors for a more aggressive clinical course in CLL. 27 CLL with somatic mutations in the IgV H genes (M-CLL) or low ZAP-70 expression (ZAPÀ) have a much better prognosis. Our results suggest that the apoptosis inducing effect of deguelin is not significantly different between the M-CLL and UM-CLL samples (P ¼ 0.62) or the ZAP þ and ZAPÀ samples (P ¼ 0.71).
Deguelin induces apoptosis in the presence of 50% human serum Two CLL samples, CLL#4 and CLL#18 (see Table 1 ), were cultured in DMEM medium as described in Material and methods, but with the addition of 50% human serum. Both samples showed an increase of early apoptotic cells (6.41 and 8.3%, respectively) after 24 h incubation with deguelin, compared to the untreated control samples. At 48 h deguelin treatment resulted in a drop of viability to 27 and 62%, respectively. These results show that human serum does not have an inhibitory effect on the action of deguelin in vitro.
Deguelin induces apoptosis in the CD19-positive cells of CLL samples, cultured in serum-free AIM-V medium, but not in healthy donor samples B-CLL cell samples and mononuclear cell samples from healthy donors were cultured in serum-free AIM-V medium and treated with 10 À6 M deguelin for 48 h. This experiment was performed to further explore the specificity of deguelin for the induction of apoptosis in the malignant cells and to avoid the possibility that deguelin only accelerates spontaneous apoptosis, which can be reduced by using AIM-V medium. 28 Results are shown in Figure 3 . Deguelin increased the percentage apoptotic (Annexin positive) CD19-positive cells in the B-CLL samples. In contrast, no increase of apoptotic CD19-positive cells could be detected in the healthy donor samples. These results show that deguelin induces apoptosis in CLL 
Deguelin inhibits the expression of IkBa in B-CLL samples
Expression of IkBa protein was evaluated by western blot analysis on protein extracts of three CLL samples cultured in serum-free AIM-V medium and either mock or deguelin treated. IkBa protein levels in CLL cells were reduced after 24 h treatment with deguelin at 10 À5 M concentration. Figure 4 shows the IkBa protein which was detected at 37 kDa according to the Molecular weight standard included in the western blot experiment. Actin blotting shows equal protein loading in each sample and was performed after stripping the initial IkBa blot. These results indicate that deguelin promotes IkBa protein degradation in CLL cells. The interaction of deguelin with the NFkB pathway in CLL cells was confirmed by an electrophoretic mobility shift assay (EMSA) (Supplementary Information).
Activation of caspases during deguelin-induced apoptosis
To determine if the pro-apoptotic effect of deguelin was accompanied by activation of caspases, we examined the processing of caspase-9 and caspase-3 by western blot analysis using specific antibodies recognizing pro-caspase-9 and the active cleavage fragments of caspase-3. Caspase-8 cleavage was evaluated by flow cytometric analysis. Figure 5 demonstrates that the levels of pro-caspase-9 were reduced in all B-CLL samples tested (n ¼ 4) after 24 h treatment with 10 À6 M deguelin compared to mock treatment. The levels of the cleaved caspase-3 increased markedly in all samples tested (n ¼ 4) ( Figure 5 ). To confirm the activation of caspase-3, we examined cleavage of the DNA repair enzyme PARP, one of the major substrates of activated caspase-3. PARP (116 kDa) is cleaved into two fragments, an N-terminal DNA-binding domain (24 kDa) and a C-terminal catalytic domain (85 kDa). Deguelin-induced cleavage of PARP was observed in all B-CLL samples tested (n ¼ 4) ( Figure 5) .
We used the total intensity of all PARP fragments to evaluate protein loading and to normalize the expression data. We could not detect cleavage of Caspase-8 (data not shown). These data indicate that deguelin induces cell death of B-CLL cells through an apoptotic mechanism dependent on caspase-9 and caspase-3 activation.
Deguelin affects pro-and anti-apoptotic proteins
To further elucidate the mechanism behind this pro-apoptotic effect, we investigated the effect of deguelin on pro-and antiapoptotic proteins. Therefore, we analyzed the conformational change of Bax and the expression levels of Bcl-xl and Mcl-1.
According to Bellosillo et al., 29 the involvement of Bax on deguelin-induced apoptosis was analyzed by means of an antibody directed against the N-terminal region of Bax (Clone YTH-6A7). This region is occluded in unstressed intact cells and hence is not available for binding by Bax N-terminal epitope specific antibodies.
30,31 Figure 6 shows the staining of In contrast, no effect on the expression of the anti-apoptotic Bcl-xl was observed (data not shown). In addition, Figure 7 shows a strong downregulation of the active full-length Mcl-1 (L) and a corresponding upregulaition of the inactive Mcl-1 cleavage fragment (S). Mcl-1 is a pro-survival member of the Bcl-2 family of apoptotic regulatory proteins whose expression levels in B-CLL cells are associated with response to treatment both in vivo and in vitro. 32, 33 Previous studies in tissue culture have shown that persistent Mcl-1 expression is strongly associated with resistance to chlorambucil and fludarabine. 32 Clinical studies have demonstrated that low Mcl-1 levels are found in patients who achieved complete remission after treatment. 33 In the untreated B-CLL samples, the ratio Mcl-1(L)/Mcl-1(S) (9.1 s.d. 3.8, n ¼ 4) was found to be 715-fold higher than the ratio Mcl-1(L)/Mcl-1(S) after treatment with deguelin, (0.62 s.d. 0.5, n ¼ 4).
We can conclude that apart from an effect on caspases, deguelin significantly alters the ratio of pro-and anti-apoptotic proteins, which increases the sensitivity of the cells to apoptotic signals.
Deguelin induces apoptosis in the presence of IL-4
IL-4 induces PI3K-dependent Akt phosphorylation and has a pro-survival effect on B-CLL cells. 34 We added IL-4 (25 ng/ml) to the B-CLL cultures to examine if deguelin was able to induce apoptosis in the presence of this survival promoting factor. As expected, IL-4 treatment reduced the percentage of apoptotic cells in the untreated control condition from 18.26 (s.d. 10.87, n ¼ 4) to 3.03% (s.d. 2.50, n ¼ 4) after 24 h. In the presence of deguelin, the pro-survival effect of IL-4 was decreased with 9.74% (s.d. 6.32, n ¼ 4). These data indicate that deguelin has a pro-apoptotic effect on B-CLL cells even in the presence of the pro-survival factor IL-4 ( Figure 8 ).
Discussion
B-CLL is the most frequent adult leukemia in the Western world, where it accounts for about 25% of all leukemias. 35 The gradual accumulation of leukemic cells in B-CLL is thought to be due to a dysregulation of apoptotic pathways and abrogation of programmed cell death. 18, 36, 37 We investigated whether deguelin, a natural compound recently described to have potential as a cancer chemopreventive or inhibitor of carcinogenesis, 3, 38 was able to enhance apoptosis of B-CLL cells in vitro. Deguelin induced apoptosis in the majority of B-CLL cells and was found to be more toxic toward B-CLL cells than to normal PBMCs, suggesting greater susceptibility of the malignant cells. The deguelin-induced apoptosis was characterized by activation of caspase-9 and caspase-3, cleavage of PARP and an alteration in the presence of pro-and anti-apoptotic proteins. Exposure of B-CLL cells to deguelin resulted in the conformational change of Bcl2-associated protein (Bax) and downregulation of the key survival protein myeloid cell leukemia sequence 1 (Mcl-1). The expression of the anti-apoptotic Bcl-xl was not altered. Interestingly, survival stimulating factors such as IL-4 and human serum did not abrogate the pro-apoptotic effect of deguelin. We also found that deguelin reduces the amount of IkBa protein in CLL cells, which indicates that it interacts with the NFkB pathway.
There is an increasing interest in the use of natural products for treatment of malignant disease. 38 Several natural products, including honokiol, triterpenoids, bryostatin 1 and (À)-epigalocatechin gallate (EGCG), a polyphenol found in green tea, and their synthetic derivates have previously been described to demonstrate activity against B-CLL cells. 22, [39] [40] [41] [42] At least, EGCG has recently been reported to have a clinical effect in B-CLL Deguelin induces apoptosis in B-CLL B Geeraerts et al treatment. 43 We evaluated in this study if deguelin may be an effective therapeutic agent in the treatment of B-CLL.
According to Chen et al., 14 who found that deguelin induces apoptosis in U937 cells and inhibits expression of IkBa in Raji and U937 cells, we evaluated the expression of IkBa protein in CLL cells. Interestingly, our results show that deguelin also reduces the expression of IkBa protein and induces apoptosis in CLL cells. Despite these results, the precise mechanism of IkBa protein downregulation and subsequent induction of apoptosis by reducing activity of NFkB is not known yet. Chen et al.
14 hypothesized a mechanism, but further investigations on the precise interaction of deguelin on the NFkB pathway are warranted.
Following Battle et al., 22 who evaluated the in vitro efficiency of Honokiol for the treatment of B-CLL, we focused on the expression of Mcl-1 to determine whether deguelin can modulate proteins important in promoting the survival of B-CLL cells and which are associated with prognosis. The decision to choose Mcl-1 expression as the key factor was based on following observations: Mcl-1 is a member of the Bcl-2 gene family, including both pro-and anti-apoptotic factors. An alteration in the balance of the corresponding proteins is commonly found in hematologic malignancies (for a review, see Kitada et al. 44 and Kitada and Reed 45 ). A high ratio of Bcl-2/ Bax and high levels of Mcl-1 are considered to contribute to the pathogenesis of B-CLL. 32, 46 Of importance, an association between high Mcl-1 expression and the ability to achieve complete remission has been reported, indicating that higher Mcl-1 protein expression is an indicator of adverse outcome for B-CLL patients. 33 Treatment of B-CLL cells with deguelin reduced expression of active full-length Mcl-1, and a corresponding increase of the inactive cleaved Mcl-1 fragment. Downregulation of Mcl-1 presumably alters the balance of pro-and anti-apoptotic proteins and would facilitate mitochondrial activation of programmed cell death. Mcl-1 expression is emerging as a prognostic determinant of outcome and response. 45 Our finding that treatment of B-CLL cells with deguelin downregulates the Mcl-1 expression may bear significant clinical relevance.
Despite these promising results, many factors can interfere with the activity of a compound during in vivo application. Recently, Flinn et al. 47 described that flavopiridol administered as a 24-h continuous infusion in B-CLL lacks clinical activity. Although in vitro experiments showed that this drug was able to kill B-CLL cells. [48] [49] [50] This discrepancy appeared to be the result of human serum albumin binding of flavopiridol, although it did not bind to fetal calf serum. 47 In addition, a slowing of chlorambucil-induced killing was reported to be due to antiapoptotic signaling by plasma components and not by sequestration of the drug by plasmaproteins. 51 Indeed, it is known that plasma activates Akt/protein kinase B signaling, and enhances the basal survival and resistance to DNA-damageinduced apoptosis in B-CLL. 51 To evaluate the impact of human serum on the activity of deguelin, we treated B-CLL cells with deguelin in the presence of 50% human serum. No reduced activity was observed. Other À6 M deguelin and data are shown as mean7standard deviation. P-value was obtained using the Student's t-test. Patients included are indicated by their patients ID as found in Table 1 . B-CLL, B-cell chronic lymphocytic leukemia; DMSO, dimethyl sulfoxide.
Deguelin induces apoptosis in B-CLL B Geeraerts et al survival factors described to prevent apoptosis of B-CLL lymphocytes include IL-4, interferon-g (IFN-g), IFN-a, IL-2, IL-6, IL-8, IL-13 and stromal cell-derived factor-1. IL-4 is the most studied interleukin in preventing ex vivo apoptosis of B-CLL lymphocytes. Interestingly, IL-4 has previously been described to induce phosphorylation of Akt in B-CLL cells. Furthermore, IL-4 has been shown to prevent apoptosis induced by glucocorticoids, IL-5, IL-10, chlorambucil and fludarabine. It has been suggested that this protective effect of IL-4 is one of the mechanisms of acquired drug resistance in B-CLL. 52 Therefore, we evaluated the response to deguelin treatment in the presence of 25 ng/ml IL-4 and noticed that IL-4 did not counteract the proapoptotic effect of deguelin on B-CLL cells. These data indicate that deguelin is able to induce apoptosis in B-CLL in the presence of pro-survival signals and thus merits further investigation for clinical application either as a single agent or in combination with other anticancer agents.
Interestingly, deguelin can be safely administered intravenously and studies on its pharmacokinetics have already been performed in rats. 53 The results of this study showed that 10 À6 M deguelin is achievable in a variety of tissues in vivo after intravenous delivery. Moreover, this dosage is not toxic to rats.
In conclusion, deguelin may be an effective therapeutic agent in the treatment of B-CLL, and thus, we encourage further investigation on the clinical impact of deguelin in B-CLL.
